TCL Archive ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication February 17, 2012
TCL Archive Intermittent Androgen Deprivation Therapy Not Equal to Continuous Treatment, Study Finds April 26, 2013
TCL Archive Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34% June 28, 2013
TCL Archive Safety Concerns About Saltz Regimen Were Statistical Artifact, ODAC Finds. December 14, 2001
